ChromaDex Corporation (CDXC) ニュース

ChromaDex to Join Russell 2000® Index

ChromaDex continues to drive innovation and growth with its proprietary Tru Niagen® supplement, backed by strong financial performance and a...

Milestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)

NR improved the six-minute walking distance and treadmill walking time for those with PAD ChromaDex Corp. (NASDAQ:CDXC), the global authority on...

ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)

Clinical study results demonstrated that Niagen IV had no adverse side effects, provided superior tolerability, and a 75% shorter infusion time...

ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)

ChromaDex plans to conduct additional studies on NRC in anticipation of filing for an Investigational New Drug Application (IND) for the...

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced today that...

ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

ChromaDex Corp. (NASDAQ: CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy-aging research, today announced that...

ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award

Judges award Niagen for its “high-quality, unparalleled” healthy aging research ChromaDex Corp. (NASDAQ:CDXC...

ChromaDex Corporation Reports First Quarter 2024 Financial Results

Total net sales of $22.2 million, gross margin of 60.7%, a net loss of $0.5 million and a positive Adjusted EBITDA of $0.7 million for the three...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement

New ingredient collaboration debuts Solgar’s first NAD+ boosting supplement and reinforces NIAGEN as the gold standard in the NAD+ supplement...

ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®

Tru Niagen is now available at 700 retail locations of The Vitamin Shoppe and Super Supplements™ and online at...

ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced that it...

ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market

Tru Niagen® expands to health-conscious Sprouts consumers in more than 400 locations across 23 states ChromaDex Corp. (NASDAQ:CDXC), the global...

ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program

All Tru Niagen products (except Tru Niagen 1,000mg, which is NSF Certified for Sport®) are Alkemist Assured...